We are live on ! Find out more
SC

Stralem & Co Portfolio holdings

AUM $157M
1-Year Est. Return 4.29%
This Fund
S&P 500
This Quarter Est. Return
+0.56%
1 Year Est. Return
+4.29%
3 Year Est. Return
+25.48%
5 Year Est. Return
+55.56%
10 Year Est. Return
–
AUM
$840M
AUM Growth
-$23.1M
Cap. Flow
-$23.5M
Cap. Flow %
-2.79%
Top 10 Hldgs %
32.67%
Holding
54
New
1
Increased
3
Reduced
40
Closed
–

Top Buys

Rank Stock Value
1
JCI icon
Johnson Controls International
JCI
+$2.89M
2
ADM icon
Archer Daniels Midland
ADM
+$208K
3
ABT icon
Abbott
ABT
+$43.4K
4
GILD icon
Gilead Sciences
GILD
+$22.3K

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$2.05M
2
MRK icon
Merck
MRK
+$1.78M
3
FDX icon
FedEx
FDX
+$1.75M
4
EOG icon
EOG Resources
EOG
+$1.5M
5
XOM icon
ExxonMobil
XOM
+$1.43M

Sector Composition

Rank Sector Weight
1 Healthcare 25.4%
2 Communication Services 12.68%
3 Energy 9.66%
4 Technology 9.63%
5 Consumer Staples 9.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVS icon
26
CVS Health
CVS
$121B
$21.5M 2.56%
272,070
-1,530
-0.6% -$124K
EOG icon
27
EOG Resources
EOG
$75.1B
$19.1M 2.27%
188,730
-15,370
-8% -$1.5M
CVX icon
28
Chevron
CVX
$386B
$18.9M 2.25%
160,640
-9,710
-6% -$1.06M
CB icon
29
Chubb
CB
$132B
$18.6M 2.21%
140,675
-5,475
-4% -$698K
XOM icon
30
ExxonMobil
XOM
$657B
$17.8M 2.12%
197,173
-16,312
-8% -$1.43M
CELG
31
DELISTED
Celgene Corp
CELG
$17.3M 2.06%
149,674
-6,110
-4% -$680K
JNJ icon
32
Johnson & Johnson
JNJ
$629B
$17M 2.03%
147,650
-8,260
-5% -$954K
TMO icon
33
Thermo Fisher Scientific
TMO
$223B
$16.7M 1.99%
118,185
-7,030
-6% -$1.04M
AMGN icon
34
Amgen
AMGN
$225B
$15.8M 1.88%
107,870
-1,955
-2% -$294K
ABT icon
35
Abbott
ABT
$192B
$15.3M 1.83%
399,310
+1,095
+0.3% +$43.4K
BMY icon
36
Bristol-Myers Squibb
BMY
$130B
$2.64M 0.31%
45,100
-1,500
-3% -$82K
KO icon
37
Coca-Cola
KO
$373B
$2.08M 0.25%
50,100
-2,000
-4% -$83.2K
ADP icon
38
Automatic Data Processing
ADP
$107B
$1.33M 0.16%
12,900
– –
BRK.B icon
39
Berkshire Hathaway Class B
BRK.B
$1.09T
$1.22M 0.15%
7,500
– –
FE icon
40
FirstEnergy
FE
$27.2B
$1.01M 0.12%
32,500
– –
AAPL icon
41
Apple
AAPL
$4.41T
$950K 0.11%
32,800
– –
LLY icon
42
Eli Lilly
LLY
$1.09T
$927K 0.11%
12,600
– –
COST icon
43
Costco
COST
$421B
$897K 0.11%
5,600
– –
CL icon
44
Colgate-Palmolive
CL
$73.6B
$831K 0.1%
12,700
– –
A icon
45
Agilent Technologies
A
$41.9B
$816K 0.1%
17,900
– –
IFF icon
46
International Flavors & Fragrances
IFF
$21.4B
$766K 0.09%
6,500
– –
ZBH icon
47
Zimmer Biomet
ZBH
$18.7B
$691K 0.08%
6,901
– –
GILD icon
48
Gilead Sciences
GILD
$168B
$687K 0.08%
9,600
+300
+3% +$22.3K
RTX icon
49
RTX Corp
RTX
$300B
$526K 0.06%
7,627
-1,112
-13% -$73.7K
SO icon
50
Southern Company
SO
$106B
$516K 0.06%
10,500
-1,600
-13% -$78.6K
1
2
3

Similar funds

LI
Leap Investments Chicago, Illinois $152M AUM 3.6% 1-Year Est. Return
BC
Blackstart Capital New York $151M AUM 14.01% 1-Year Est. Return
JT
Jump Trading Chicago, Illinois $150M AUM 17.61% 1-Year Est. Return
SCM
Stellar Capital Management Phoenix, Arizona $147M AUM 5.91% 1-Year Est. Return
HF
Hellman & Friedman San Francisco, California $169M AUM
SMFS
Squar Milner Financial Services Irvine, California $176M AUM 10.56% 1-Year Est. Return
CCM
Cloverdale Capital Management Dallas, Texas $135M AUM 13.89% 1-Year Est. Return
CCM
Castine Capital Management Boston, Massachusetts $129M AUM 23.45% 1-Year Est. Return

Stralem & Co's Q4 2016 Portfolio in Review

As of Q4 2016, Stralem & Co held 54 positions worth $840M, down 2.7% from $863M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Trading was light in Q4 2016: portfolio turnover was 1.9%. Stralem & Co opened 1 new position and made no exits, leaving the 54-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 26% a quarter earlier, followed by Communication Services and Energy.

  • Stralem & Co's largest Q4 2016 buy was Archer Daniels Midland: 4,700 shares worth $215K.
  • Stralem & Co added most to Johnson Controls International in Q4 2016, an estimated $2.89M increase.
  • Stralem & Co's biggest Q4 2016 reduction was UnitedHealth, cutting an estimated $2.05M.
  • Stralem & Co's ten largest holdings make up 33% of its $840M portfolio in Q4 2016.
  • Stralem & Co opened 1 new position and closed 0 in Q4 2016.
  • Stralem & Co's portfolio value fell 2.7% quarter-over-quarter to $840M.

Based on Stralem & Co's 13F filing for Q4 2016, filed 23 Jan 2017.